Key result
Higher 2-h post-MMTT glucose and CGM measures were associated with higher odds of intermediate or high 10-year CVD risk (ORs 1.21-1.70, p<0.001) in adults without diabetes.
Why the study?
Prediabetes and diabetes are established CVD risk factors, but how dynamic glucose fluctuations relate to CVD risk in individuals without diabetes remains unclear.
Do CGM-derived measures and 2-h post-MMTT glucose associate with estimated 10-year CVD risk in adults without diabetes?
Observational (n=1,374)
Do CGM-derived measures and 2-h post-MMTT glucose associate with estimated 10-year CVD risk in adults without diabetes?
Answers are grounded in this paper and cite their sources.
Dynamic measures of glycemia, such as CGM-derived metrics and post-MMTT glucose, are associated with higher estimated 10-year CVD risk in adults without diabetes, independent of fasting plasma glucose.
Introduction and Objective: Prediabetes and diabetes are well-established risk factors for CVD; yet how dynamic glucose fluctuations relate to CVD risk in those without diabetes remains unclear. Methods: We included 1374 Framingham Heart Study participants free of diabetes and CVD (3rd Generation, Exam 4), who had ≥3 days of continuous glucose monitor (CGM) and completed a mixed meal tolerance test (600kcal MMTT; 75g carbohydrate, 21g fat, 29g protein). The 10-year total CVD risk was estimated using the Predicting Risk of CVD EVENTs (PREVENT) base equations. We performed multinomial regression to relate standardized CGM-derived measures and 2-h post-MMTT glucose with PREVENT categories (low <5%[reference], borderline 5-<7.5%, intermediate/high ≥7.5%), and linear regression for log-transformed PREVENT scores (continuous). All models were adjusted for fasting plasma glucose (FPG). Results: Among participants (55.8% female, 56% normoglycemic), the mean age was 59.3y and BMI was 27.9kg/m². Higher 2-h post-MMTT glucose and CGM measures (including mean glucose and time >140mg/dL) were associated with higher odds of intermediate/high CVD risk (ORs: 1.21-1.70, all p<0.001), and a higher overall 10-year CVD risk (per 1 SD increase, β:0.07-0.16, all p<0.001), adjusting for FPG (Figure). Conclusion: Dynamic measures of glycemia may serve as biomarkers that precede development of overt dysglycemia, potentially providing additional integrated information about potential CVD risk, independent of FPG. Disclosure B. Bakhshi: None. V. Xanthakis: None. H. Lin: None. J.M. Murabito: None. D. Steenkamp: Research Support; Current; Abbott Diabetes. Research Support; Ended; Novo Nordisk Foundation. Research Support; Current; Insulet Corporation. D.M. Lloyd-Jones: None. M. Nayor: None. M.E. Walker: None. N. Spartano: Research Support; Current; Dexcom, Inc.
No takes yet. Share an insight, caveat, or question.
Bakhshi et al. (2026) conducted an observational in Adults without diabetes and cardiovascular disease (n=1,374). Higher 2-h post-MMTT glucose and CGM measures was evaluated on Intermediate/high 10-year CVD risk (PREVENT score ≥7.5%) (OR 1.21-1.70, p=<0.001). Higher 2-h post-MMTT glucose and CGM measures were associated with higher odds of intermediate or high 10-year CVD risk (ORs 1.21-1.70, p<0.001) in adults without diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: